These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25482341)

  • 1. Theoretical impact on coronary disease of using a computerized clinical decision support system in the prescription of lipid-lowering treatment.
    Zamora A; Carrion C; Vázquez-Oliva G; Paluzie G; Martín-Urda A; Elosua R
    Rev Esp Cardiol (Engl Ed); 2015 Jan; 68(1):75-8. PubMed ID: 25482341
    [No Abstract]   [Full Text] [Related]  

  • 2. The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Introduction.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):1M. PubMed ID: 9766340
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lipid factors and evolution of the atherosclerotic plaque: review of recent trials].
    Scardi S
    G Ital Cardiol; 1996 Dec; 26(12):1481-93. PubMed ID: 9162677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease.
    Kauffman AB; Olson KL; Youngblood ML; Zadvorny EB; Delate T; Merenich JA;
    J Clin Lipidol; 2010; 4(3):173-80. PubMed ID: 21122649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease.
    Brown BG; Zhao XQ; Sacco DE; Albers JJ
    Annu Rev Med; 1993; 44():365-76. PubMed ID: 8476257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences in achieving optimal lipid goals in patients with coronary artery disease.
    Victor BM; Teal V; Ahedor L; Karalis DG
    Am J Cardiol; 2014 May; 113(10):1611-5. PubMed ID: 24698458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development.
    Orloff DG
    Am J Cardiol; 2001 Feb; 87(4A):35A-41A. PubMed ID: 11243603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlates of repeat lipid testing in patients with coronary heart disease.
    Virani SS; Woodard LD; Wang D; Chitwood SS; Landrum CR; Urech TH; Pietz K; Chen GJ; Hertz B; Murawsky J; Ballantyne CM; Petersen LA
    JAMA Intern Med; 2013 Aug; 173(15):1439-44. PubMed ID: 23817669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease the incentives to order lipid panels.
    McConnell M; Downs JR; Good CB
    JAMA Intern Med; 2014 Mar; 174(3):473. PubMed ID: 24590082
    [No Abstract]   [Full Text] [Related]  

  • 12. Decrease the incentives to order lipid panels--reply.
    Virani SS; Ballantyne CM; Petersen LA
    JAMA Intern Med; 2014 Mar; 174(3):473-4. PubMed ID: 24590083
    [No Abstract]   [Full Text] [Related]  

  • 13. Workshop VI--Regression of atherosclerosis: what does it mean?
    Brown BG
    Am J Med; 1991 Feb; 90(2A):53S-55S. PubMed ID: 1994718
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent trials of lipid lowering.
    Ray KK; Cannon CP; Braunwald E
    Int J Clin Pract; 2007 Jul; 61(7):1145-59. PubMed ID: 17577297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary arteriography and lipid lowering: limitations, new concepts, and new paradigms in cardiovascular medicine.
    Gould KL
    Am J Cardiol; 1998 Sep; 82(6A):12M-21M. PubMed ID: 9766343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum cholesterol during the course of acute coronary events and secondary prevention of coronary heart disease].
    Garrido Sanjuán JA; Pía Iglesias G; Sesma Sánchez P
    An Med Interna; 2001 Sep; 18(9):464-7. PubMed ID: 11715132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The problem of overuse.
    Covinsky KE
    JAMA Intern Med; 2013 Aug; 173(15):1446. PubMed ID: 23817453
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician performance measurement: the importance of understanding physician behavior.
    Drozda JP
    JAMA Intern Med; 2013 Aug; 173(15):1444-6. PubMed ID: 24141974
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation of lipoprotein (a) concentration with the extent of coronary artery disease in patients on lipid lowering therapy.
    Malek F; Dvorak J; Svitil J; Skalnikova V; Mates M; Kmonicek P; Formanek P; Aschermann O; Kopriva K; Neuzil P
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():55-9. PubMed ID: 23183511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
    Voros S; Joshi PH; Vazquez G; Roth G; Murrieta L; Rinehart S; Qian Z; Miller J
    J Cardiovasc Comput Tomogr; 2010; 4(3):164-72. PubMed ID: 20413364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.